The COVID-19 coronavirus epidemic that originated in Wuhan, the capital of China’s Hubei province, has wide-ranging implications for the pharmaceutical industry and healthcare sector alike.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.